Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Repare Therapeutics Inc. RPTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • CA • USD

SharesGrow Score
58/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$18.33
+591.7%

Repare Therapeutics Inc. (RPTX) is a Biotechnology company in the Healthcare sector, currently trading at $2.65. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is RPTX = $18 (+591.7% upside).

Financials: revenue is $53M, +526%/yr average growth. Net income is $85M (loss), growing at -46.8%/yr. Net profit margin is -158.4% (negative). Gross margin is 96.4% (+40.4 pp trend).

Balance sheet: total debt is $2M against $151M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 6.77 (strong liquidity). Debt-to-assets is 1.1%. Total assets: $177M.

Analyst outlook: 7 / 9 analysts rate RPTX as buy (78%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 85/100 (Pass), Income 10/100 (Fail).

$18.33
▲ 591.7% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Repare Therapeutics Inc., the average price target is $18.33, with a high forecast of $30.00, and a low forecast of $10.00.
Highest Price Target
$30.00
Average Price Target
$18.33
Lowest Price Target
$10.00

RPTX SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RPTX

✓
VALUE Pass
100/100
RPTX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $18, implying +579.2% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
RPTX: +526%/yr revenue is, -46.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet RPTX: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 6.77 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
RPTX: Gross margin is 96.4% (+40.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 7 / 9 analysts rate RPTX as buy (78%). Analyst consensus target is $18 (+579.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
RPTX: Net profit margin is -158.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.89-2.66
Volume1.17M
Avg Volume (30D)1.18M
Market Cap$114.24M
Beta (1Y)0.96
Share Statistics
EPS (TTM)-2.00
Shares Outstanding$42.41M
IPO Date2020-06-19
Employees129
CEOSteve Forte
Financial Highlights & Ratios
Revenue (TTM)$53.48M
Gross Profit$51.56M
EBITDA$-93.52M
Net Income$-84.69M
Operating Income$-93.52M
Total Cash$152.79M
Total Debt$1.93M
Net Debt$-82.78M
Total Assets$176.51M
Price / Earnings (P/E)-1.3
Price / Sales (P/S)2.14
Analyst Forecast
1Y Price Target$15.00
Target High$30.00
Target Low$10.00
Upside+466.0%
Rating ConsensusBuy
Analysts Covering9
Buy 78% Hold 22% Sell 0%
Price Target Summary
Company Info
CountryCA
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS7602731025

Price Chart

Track all markets on TradingView
RPTX
Repare Therapeutics Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.89 52WK RANGE 2.66

People Also View

RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 FUSN
FUSN
Fusion Pharmaceuticals Inc.
$21.55
+0.14%
 NRIX
NRIX
Nurix Therapeutics, Inc.
$16.30
+2.45%
 ACCD
ACCD
Accolade, Inc.
$7.02
+0.00%
 MASS
MASS
908 Devices Inc.
$7.32
+1.67%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message